Navigation Links
Celator(R) Pharmaceuticals Enrolls First Patient in Its Phase 2 Study of CPX-351 in Acute Myeloid Leukemia in First Relapse
Date:3/10/2009

The study is supported by The Leukemia & Lymphoma Society(R)

PRINCETON, N.J., March 10 /PRNewswire/ -- Celator Pharmaceuticals today announced that the first patient has been treated in its Phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus intensive salvage therapy in adult patients (up to 60 years old) with acute myeloid leukemia in first relapse. As previously announced, the study is being supported through a partnership with The Leukemia & Lymphoma Society (LLS).

The first patient was enrolled by Maureen Cooper, M.D., at St. Francis Hospital in Beech Grove, Indiana. "We are pleased to be participating in this study and eager to collect additional clinical evidence demonstrating the benefit of delivering and maintaining a synergistic ratio of these two widely used drugs for the treatment of AML," said Dr. Cooper.

"CPX-351 represents a unique approach to enhancing the clinical benefit of the two most active drugs used in the treatment of patients with AML," said Jonathan Kolitz, M.D., Director of the Leukemia Service at North Shore University Hospital and lead investigator for the study. "There is no standard of care established for patients in first relapse. We expect that this study will build on the promising results initially obtained in this patient population in the Phase 1 study and provide additional confirmation of the clinical benefit of CPX-351."

The study (Protocol CLTR0308-205) will enroll up to 120 patients between the ages of 18 and 60 who have pathological confirmation of relapsed AML after an initial complete response to prior therapy lasting at least one month. Patients will be randomized (2:1) to receive either CPX-351 (100u/m2; Days 1, 3, 5) or one of several control arm regimens, including high dose cytarabine with or without daunorubicin; conventional "7+3" (cytarabine/daunorubicin reg
'/>"/>

SOURCE Celator Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Frederick R. Appelbaum, M.D. and Ross C. Donehower, M.D. Join Scientific Advisory Board of Celator(R) Pharmaceuticals
2. Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting
3. Celator(R) Pharmaceuticals To Present at Biotech Showcase 2009
4. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
5. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
6. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
7. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
9. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
11. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Alba,s research at the University of Huddersfield could help ... popular emulsion-based food products such as butter, mayonnaise, ... to gain an international profile for her work. , ... science at the University and now she has embarked ... supervisor, Dr Vassilis Kontogiorgos, she is investigating the potential ...
(Date:7/10/2014)... says the human brain operates much the same whether ... provide a better understanding of schizophrenia, bipolar disorder and ... 13.6 million Americans. , In newly published research in ... professor at the Center for Molecular and Behavioral Neuroscience, ... at rest is basically the same as that of ...
(Date:7/10/2014)... at sarcomas research group at the Bellvitge Biomedical Research ... have been tested in 19 patients a new therapeutic ... which indicate that the new treatment could stabilize the ... in the British Journal of Cancer ., ... and complex since there are several subtypes. It can ...
(Date:7/10/2014)... 10, 2014) Men who experience hot flashes are ... find relief from their silent suffering if they ... findings from a Baylor University case study., After seven ... had uncontrolled hot flashes following prostate cancer surgery showed ... also an impressive improvement in sleep quality, according to ...
(Date:7/9/2014)... of low back pain are not linked to weather ... and precipitation. Findings published in Arthritis Care & ... Rheumatology (ACR), indicate that the risk of low back ... gusts, but was not clinically significant. , According ... low back pain at some point in their life, ...
Breaking Medicine News(10 mins):Health News:World interest in research work on the benefits of the Okra plant 2Health News:Working to loosen the grip of severe mental illness 2Health News:New therapeutic combination to slow resistant sarcomas 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 3Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 4Health News:Low back pain? Don't blame the weather 2
... die hard chocó fans could crack open a bar of ... its true colors and bares// its heart! When you melt ... a new finding. ,Researchers in the United ... an 18-month study to gauge the influence of aspirin on ...
... – whether from holiday feasts or rich desserts or alcoholic ... ,Heartburn – generally caused by naturally occurring acids ... by a characteristic burning sensation that sufferers describe as rolling ... in this process. ,“Most of the time heartburn ...
... The health crisis triggered by the death of over ... health institution's laboratory, has prompted Panamanian President// Martin Torrijos ... ,Torrijos said that the government had since ... Security Body (CSS), permanently in a bid to win ...
... A report released in the state of Pennsylvania, U.S,reveals that ... there in 2005.// ,The report the ... kind in various hospitals spread all over the state released ... have contracted hospital acquired infections when admitted there for some ...
... The genes of progeny are dependant on a fairly ... is potent enough to impact the genes of the ... consumed by expectant mice were seen to impact generation ... the National Academy of Sciences., ,To quote the ...
... Paris- Scientists from the Mecca of Fashion, Paris, have ... presence of a natural chemical called opiorphin//, a natural ... morphine., ,In their experiments, rodents were found to ... chemical in comparison with the usual dosage of morphine. ...
Cached Medicine News:Health News:Holiday Season Could Ring in “Heartburn Season 2Health News:Holiday Season Could Ring in “Heartburn Season 3Health News:Hospital infections gaining ground in Pennsylvania hospitals 2
(Date:1/15/2014)... GENEVA, Ill. , Jan. 15, 2014 The ... a Medical Fitness Center by the Medical Fitness Association, ... centers to achieve their full potential. The Cadence Fitness ... in the western suburbs and second in the Chicagoland ...
(Date:1/15/2014)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") ... its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for ... Solta Medical, Inc. (NASDAQ: SLTM ) ("Solta") ...
(Date:1/15/2014)... Jan. 15, 2014  A novel wearable injector slightly larger than ... for patients to self-inject prescription drugs in the large doses ... blood diseases, autoimmune deficiencies, and genetic disorders.  ... $220B by 2018, according to analysts.   Many of these drugs ...
Breaking Medicine Technology:Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... Inc. (Nasdaq: OPTR ) announced today the ... 3 trials in patients with Clostridium difficile ... Infectious Disease Society of America (IDSA) in Vancouver, British ... M.D., of the University of Oxford, presented combined data ...
... PARK, Kan., Oct. 22 Mid*Lands IRB, LLC is ... by the Association for the Accreditation of Human Research ... Council on Accreditation.   Located in the ... board (IRB) that protects the rights and welfare of ...
Cached Medicine Technology:Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 2Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 3Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 4Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 5Mid*Lands IRB, LLC - First Independent IRB in Kansas and the Kansas City Area Awarded Accreditation for Protecting Research Participants 2
... ISI Lexan Universal K Table ... for lower and upper extremity ... neck, and lower extremity surgeries. ... gives you the ability to ...
... process makes use of ... magnetic responsiveness. The superparamagnetic ... rigid core structure ensures ... occurs upon removal of ...
... a method for isolating antibodies, antigens, ... using affinity binding, while retaining biological ... the particles to separate biotinylated molecules ... MagnaBind™ Beads from the suspension, an ...
Malaria antibody EIA 480 test kit...
Medicine Products: